Company Overview and News

 
Bursa opens higher on solid Wall Street showing

2017-08-14 themalaymailonline
KUALA LUMPUR, Aug 14 — Bursa Malaysia opened higher today in tandem with its Asian peers, taking the cue from the firmer Wall Street market last week ahead of the release of China's economic data due later today.

 
MTDC sees four tech companies listing by 2020

2017-07-06 themalaymailonline
malaysian technological development corporation sdn bhd logoSERDANG, July 6 — Malaysian Technology Development Corp Sdn Bhd (MTDC) expects at least four technology companies to list on Bursa Malaysia between 2018 and 2020.

 
Tie-up with Angkasa to boost Bioalpha’s domestic earnings

2017-04-16 thestar.com.my
 KUALA LUMPUR: ACE Market firm Bioalpha Holdings Bhd, which is targeting a Main Board listing, is counting on its exclusive tie-up with national cooperative organisation Angkasa to propel its domestic earnings in the coming years alongside the positive breakthroughs that it has made in overseas markets.

 
Bursa ends lower as sentiment turns cautious

2017-04-06 themalaymailonline
An investor monitors share market prices at a brokerage firm in Kuala Lumpur. — Reuters picKUALA LUMPUR, April 6 ― Bursa Malaysia ended lower today in line with regional markets as sentiment turned cautious over US Federal Reserve's plan to cut its US$4.5 trillion (US$1 = RM4.43) balance sheet later this year.

 
KLCI falls 0.28%, slips to below 1,740 level

2017-04-06 theedgemarkets
KUALA LUMPUR (April 6): The FBM KLCI fell 0.28% and slipped to below the 1,740-point level at the midday break today, in line with the lacklustre regional markets.

 
KLCI extends loss in line with lacklustre regional market

2017-04-06 theedgemarkets
KUALA LUMPUR (April 6): The FBM KLCI extended its losses at mid-morning today, in line with the lacklustre regional markets.

 
KLCI rises 0.64%, blue chips lift

2017-03-06 theedgemarkets
KUALA LUMPUR (March 6): The FBM KLCI rose 0.64% at the midday break today, lifted by gains including at index-linked blue chips.

 
KLCI stays above 1,710-level, select blue chips lift

2017-03-06 theedgemarkets
KUALA LUMPUR (March 6): The FBM KLCI remained above the 1,710-point level at mid-morning today, lifted by select blue chips.

 
Bursa Malaysia ends lower on profit taking

2017-03-03 themalaymailonline
KUALA LUMPUR, March 3 — Bursa Malaysia ended lower today on profit taking activities across-the-board and in tandem with its regional peers.

 
Bursa shares remain in the red at mid-afternoon

2017-03-03 themalaymailonline
Market breadth was negative as losers led gainers 495 to 318 with 357 counters unchanged, 526 untraded and 14 others suspended. — Reuters picKUALA LUMPUR, March 3 — Share prices on Bursa Malaysia stay in the red at mid-afternoon, as profit takings continues in heavyweight stocks, led by trade and services counters. 

 
KLCI drops 0.41% as profit taking intensifies

2017-03-03 theedgemarkets
KUALA LUMPUR (March 3): The FBM KLCI dropped 0.41% at the midday break today as profit taking intensified at the local market.

 
KLCI dips 0.35% on mild profit taking

2017-03-03 theedgemarkets
KUALA LUMPUR (March 3): The FBM KLCI dipped 0.35% at mid-morning today on some mild profit taking, but held on to its position above the 1,700-point level.

 
KLCI falls 0.48% as key blue chips retreat

2017-01-31 theedgemarkets
KUALA LUMPUR (Jan 31): The FBM KLCI fell 0.48% at mid-morning today, weighed by key blue chips in line with the defensive regional markets.

 
KLCI falls 0.58% on renewed Trump woes

2017-01-31 theedgemarkets
KUALA LUMPUR (Jan 31): The FBM KLCI fell 0.58% at the midday break today as renewed concerns over US President Donald Trump's policy decisions kept investors on tenterhooks.

 
KLCI to extend gains, gear toward 1,652

2017-01-04 theedgemarkets
KUALA LUMPUR (Jan 5): The FBM KLCI is expected to extend its gains today and gear toward the 1,652-point level, riding on the oevrnight momentum at most global markets.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...